Immunovant (IMVT) vs Scholar Rock (SRRK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunovant (IMVT) has outperformed Scholar Rock (SRRK) over the past year, gaining 98.9% versus a gain of 6.8%. Over five years, IMVT leads with a +267.4% price change compared with +54.7% for SRRK. Immunovant is the larger company by market cap ($6.22 billion vs $5.15 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMVT | SRRK |
|---|---|---|
| Share price | $30.14 | $42.28 |
| Market cap | $6.22B | $5.15B |
| 1-day change | -5.95% | +0.18% |
| YTD return | +26.04% | -4.20% |
| 1-year return | +98.88% | +6.84% |
| 5-year return | +267.43% | +54.75% |
| EPS (TTM) | $-2.82 | $-3.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-505.61M | $-377.94M |
| 52-week high | $45.42 | $61.76 |
| 52-week low | $16.08 | $27.07 |
| Distance from 52-week high | -33.65% | -31.55% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +62.20% | +66.62% |
| Average volume | 1.22M | 1.49M |
| Shares outstanding | 206.55M | 121.79M |
| Employees | 315 | 289 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMVT has outperformed SRRK by 92.0 percentage points over the past year.
About Immunovant
IMVT stock →Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees
About Scholar Rock
SRRK stock →Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 289 employees
IMVT vs SRRK FAQ
Which is bigger, Immunovant or Scholar Rock?
Immunovant (IMVT) is larger, with a market capitalization of $6.22B compared with $5.15B for Scholar Rock (SRRK).
Which stock has performed better over the past year, IMVT or SRRK?
IMVT returned +98.88% over the past 12 months, compared with +6.84% for SRRK (price return, excluding dividends). Past performance does not predict future results.
Are Immunovant and Scholar Rock in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.